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64 Poster Session Iat transplantation.Results:NHLwas classified as aggressive in 270
patients (168 diffuse large B-cell lymphoma, 58 mantle cell lym-
phoma, 44 peripheral T cell lymphoma), and as indolent in 107 pa-
tients (follicular lymphoma). In the allo-HSCT group (related
donor: n 5 122, unrelated donor: n 5 50), 141 patients (median
age: 47 years old, range 18–64) underwent full-intensity condition-
ing (FIC) and 31 (median age: 58 years old, range 44–71) reduced-
intensity conditioning (RIC). Overall survival (OS) at 5-year in
chemosensitive patients was 46.2% (95% CI, 33.1–59.3) in the
allo-HSCT group (n 5 63) and 41.0% (30.7–51.3) in the auto-
HSCT group (n 5 176). OS in chemorefractory patients was
35.0% (5-year OS, 25.2–44.8) with survival plateau in the allo-
HSCT group (n 5 109) but only 7.4% (4-year OS, 0–20.3) in the
auto-HSCT group (n 5 29). In multivariate analysis using a Cox
hazard model for the entire cohort, chemorefractory disease (Haz-
ard ratio [HR], 1.73; 95%CI, 1.25–2.39; p5 0.001) and age over 50
(HR, 1.57; 95%CI, 1.19–2.07; p 5 0.001) were identified as signif-
icant risk factors on progression-free survival (PFS). In chemore-
fractory indolent NHL, patients with RIC had a better outcome
than auto-HSCT (p 5 0.016) or FIC (p 5 0.083), with 5-year
PFS of 56.1% (26.2–86.0) in RIC, 0% in auto-HSCT and 20.4%
(2.6–38.2) in FIC.Conclusions: Allo-HSCT has curative potential
for patients even in chemorefractory NHL. RIC for indolent NHL
provided significant PFS for patients even with chemorefractory
disease, and merits further investigation.172
PHASE I STUDY OF VACCINATIONWITH DENDRITIC CELLMYELOMA FU-
SIONS
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Wehave developed a cancer vaccine in which patient derived my-
eloma cells are fused with autologous dendritic cells (DCs). In this
way, multiple tumor antigens are presented in the context of DC de-
rived costimulatory molecules. We are conducting a phase I trial in
which multiple myeloma (MM) patients undergo serial vaccination
with DC/myeloma fusions in conjunction with GM-CSF. To date,
16 patients have been enrolled and 15 have undergone therapy. Pa-
tients underwent leukapheresis and DCs were generated from ad-
herent mononuclear cells cultured for 5 days with GM-CSF and
IL-4 and matured by exposure to TNFa. The mean yield of DCs
was 1.23  108 cells with a mean viability of 88%. Patient derived
MM cells were isolated from bone marrow aspirates. The mean
yield of MM cells was 92.5  106 cells with a mean viability of
90%. Fusion cells were generated by coculture of DCs with MM
cells in the presence of polyethylene glycol. Fusion cells were quan-
tified by determining the percentage of cells that co-expressed
unique DC and MM antigens. Mean fusion efficiency and viability
was 40% and 84%, respectively. As a measure of immunologic po-
tency, DC/MM fusions stimulated allogeneic T cell proliferation,
with mean stimulation indexes of 48, 36, and 9 for the DC, fusion
and MM cell populations, respectively. To date, 15 patients have
completed vaccination at a dose of 1–5  106 fusion cells. Adverse
events potentially related to vaccine included injection site reac-
tions, edema, rash, fever, chills, fatigue, myalgias, pruritis, and diar-
rhea. 1 patient with a history of deep venous thrombosis (DVT)
developed a DVT and pulmonary embolus of uncertain relation
to the vaccine. To date, 6/9 evaluable patients have demonstrated
immunologic response, defined by at least 2 fold increase in IFNg
expression by CD4 and/or CD8 T cells in response to ex vivo expo-
sure to autologous tumor lysate. Vaccination was associated with an
increase in circulating tumor specific T cells as evidenced by an in-
crease in CD81 cells binding the MUC1 tetramer. Humoral im-
mune responses are being assessed by SEREX analysis. 3 patients
have ongoing stable disease at 3.5, 6, and 19 months following their
initial vaccine. 6 patients demonstrated disease stability with subse-
quent progression ranging from 9weeks to 8months following their
first vaccine. Vaccination with DC/MM fusions has been well toler-
ated, associated with immunologic response, and disease stabiliza-
tion in a majority of patients with MM.173
STEM-CELL COLLECTION PRIOR TO AUTOLOGOUS STEM CELL TRANS-
PLANTATION IS IMPROVED BY CYCLOPHOSPHAMIDE IN LENALIDO-
MIDE-TREATED PATIENTS WITH MULTIPLE MYELOMA
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Introduction:Recent studies discuss difficulty in collecting stem
cells in multiple myeloma (MM) patients receiving lenalidomide-
based induction therapy using filgastrim (granulocyte-colony stim-
ulating factor [G-CSF]) in preparation for autologous stem cell
transplantation (ASCT). It has also been suggested that treatment
time beyond 4–6 cycles might hinder collection yields.Aim:To de-
termine if addition of cyclophosphamide (CTX) to G-CSF as a mo-
bilization regimen could rescue collection of adequate stem cells for
at least two ASCTs in patients who had induction therapy with the
BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/Dexa-
methasone) regimen. Method: Each 28-day cycle, patients re-
ceived: clarithromycin 500 mg po BID for days 1–28,
lenalidomide 25 mg po daily for days 1–21, and dexamethasone
40 mg po weekly on days 1, 8, 15, and 21. Patients were treatment
naive, with Stage II or III MM by Durie-Salmon criteria. Prior to
stem cell mobilization, BiRD therapy was held for a minimum of
14 days. Stem cell collection was performed after either G-CSF
alone at a dose 10mcg/kg/day for 5–10 consecutive days until a total
of 10  106/kg CD341 stem cells had been collected, or with addi-
tion of CTX at a dose of 3 g/m2 once prior to initiation of G-CSF
therapy. Results: 28 patients underwent stem cell collection. Stem
cell mobilization was attempted with G-CSF alone in 9 instances,
and with CTX1G-CSF in 20 instances (1 patient underwent mobi-
lization with both). In comparison with G-CSF alone, CTX1G-
CSF yielded a significantly greater stem cell collection (mean
CD341 cells collected: 3.78  106/kg vs. 32.33  106/kg, P \
0.0001). Only 33% of patients who attempted stem cell mobiliza-
tion with G-CSF alone obtained sufficient CD341 cell yield vs.
100% of the patients mobilized with CTX1G-CSF (P\ 0.0001).
The extent of BiRD therapy prior to stem cell mobilization ranged
from 2–27 cycles. The number of cycles of BiRD did not signifi-
cantly impact the success rate of stem cell collection (P 5 0.14).
Conclusion: The patients mobilized with CTX1G-CSF had
a higher collection of CD341 cells, and enough stem cells for
two ASCTs were harvested from them. There was no association
between duration of BiRD therapy and successful CD341 cell col-
lection. Thus, lenalidomide-based induction therapy can be contin-
ued until desired tumor reduction goal is achieved, and CTX in
addition to G-CSF should be used to ensure successful stem cell
harvest prior to ASCT.
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AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) FOR MANTLE
CELL LYMPHOMA
Mahindra, A., Copelan, E., Bolwell, B., Rybicki, L., Dean, R.,
Kalaycio, M., Sobecks, R., Ferraro, C., Cherni, K., Pohlman, B.,
Sweetenham, J. Cleveland Clinic, Cleveland, OH.
Background: Mantle cell lymphoma (MCL) is associated with
disappointing results with conventional chemotherapy. The use of
high dose therapy and ASCT for this disease is unclear. We report
here our experience with 61MCL patients (pts) treated with ASCT.
Patients andMethods: 61 pts underwent ASCT forMCL between
7/1996 and 3/2007 using a uniform preparative regimen of busul-
fan, cyclophosphamide and etoposide. 51 pts (84%) had Stage IV
disease. 48% of the pts were in first complete remission (CR1),
5% were in CR2, 25% in first partial remission (PR1), 10% in
PR2 and remaining were CR/PR 31. Results:Median age at diag-
nosis was 56 yrs (range 33–71) and at transplant was 59 yrs (range
34–72). Median time from diagnosis to ASCT was 8.3 months
(range 4.6–81). There were no deaths within 100 days of ASCT.
23 pts (38%) relapsed after ASCTat amedian of 19.8months (range
2.6–59.6). On multivariable analysis, patients transplanted in CR2
or PR2 compared to CR1 or PR1 (p\0.001, HR 5.72) had a higher
risk of relapse.
